Clinical Trials Directory

Trials / Completed

CompletedNCT02890537

Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head

Treatment of Osteonecrosis of the Femoral Head by Implantation of Preosteoblastic Cells: a Randomized, Controlled, Single Blind Pilot Study

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
82 (actual)
Sponsor
Erasme University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Non-traumatic osteonecrosis is a painful disorder of the hip characterized by a necrosis of the osteomedullary tissue, which leads to subchondral bone collapse and joint destruction. Core decompression is currently the treatment of choice for early stage osteonecrosis of the femoral head. This method consists in decompressing the rigid intra-osseous chamber to promote revascularization, thus halting progression of the disease and stimulating repair. Still this treatment remains highly controversial, since the success rates of the first studies have not been repeated. The exact pathology mechanisms involved in osteonecrosis have not yet be fully elucidated. Several hypotheses have been evoked, including fat embolism, trabecular bone microfractures, microvascular tamponade and, more recently, impaired bone and/or mesenchymal cells recruitment. Three studies have indicated the potential clinical benefits of cell-based approaches for the treatment of osteonecrosis (Hernigou 1997, Hernigou \& Beaujean 2002, Gangji et al. 2004). This is on the basis of these observations that a proprietary population of autologous osteoblastic cells (PREOB®) has been developed. This Phase 2B study aims at demonstrating the efficacy and safety of PREOB® in the treatment of early stage osteonecrosis of the femoral head. The primary goal of this study was to investigate the safety and efficacy of the implantation of the investigational product PREOB® (human autologous bone marrow-derived osteoblastic cells) in comparison to bone marrow concentrate (BMC) when implanted at the osteonecrotic lesion of the femoral head, with a follow-up period of up to 5 years.

Conditions

Interventions

TypeNameDescription
DRUGCore decompression/PREOB® implantationAll subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
DRUGCore decompression/BMC implantationAll subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).

Timeline

Start date
2003-10-01
Primary completion
2011-05-01
Completion
2015-01-01
First posted
2016-09-07
Last updated
2016-09-07

Locations

2 sites across 1 country: Belgium

Source: ClinicalTrials.gov record NCT02890537. Inclusion in this directory is not an endorsement.

Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head (NCT02890537) · Clinical Trials Directory